Pharmaceuticals in China
195 verified figures for China, covering 128 indicators from 9 primary sources. Every figure links to the report it came from.
The short version
Key takeaways
Economy
- Cumulative negotiated drug sales during agreement period in China totalled 510 billion CNY as of 31 October 2024 (State Council). State Council ↗ T1 Official
- Negotiated pharmaceutical sales driven by medical insurance in China totalled 740 billion CNY as of 28 February 2026 (NHSA). NHSA ↗ T1 Official
Other
- First-in-class drug approvals in China stood at 11 in 2025 (NHSA). NHSA ↗ T1 Official
- Innovative drug licensing-out upfront payment value in China stood at 7 billion USD in 2025 (MOFCOM). MOFCOM ↗ T1 Official
- Innovative drug out-licensing deal value in China stood at 130 billion USD in 2025 (NHSA). NHSA ↗ T1 Official
- Approved Class 1 innovative drugs in China stood at 76 in 2025 (NHSA). NHSA ↗ T1 Official
- Approved innovative drugs with new targets or mechanisms in China totalled 11 in 2025 (NHSA). NHSA ↗ T1 Official
- Bioequivalence trials in China stood at 2,218 in 2025 (NHSA). NHSA ↗ T1 Official
- Category 1 innovative drugs added to national health insurance catalog in China totalled 50 in 2025 (NHSA). NHSA ↗ T1 Official
- Class 1 innovative drug clinical trials in China stood at 2,171 in 2025 (NHSA). NHSA ↗ T1 Official
The complete table
Pharmaceuticals data for China
Every row links to its own page with the full source, verbatim quote and citation.
195 data points across 128 indicators. Each line shows the latest value; open a line for earlier periods and forecasts.
IndicatorPeriodValueSourceType
Alzheimer's disease innovative drug clinical trial approvals (multi-year total)2023–20248NMPAT12024actual→
Antibody-drug conjugate approvals20253DIAT22025actual→
Approved Class 1 innovative drugs202576NHSAT12025actual→
Approved Class 1 innovative drugs (half year)as of 30 Jun 202638NHSAT12026actual→
Approved drug marketing registration applications (half year)as of 30 Jun 20262,318NHSAT12026actual→
Approved innovative drugs designated as breakthrough therapies +1 more 202413State CouncilT12024actual→
Approved innovative drugs growth rate202558.3%MOFCOMT12025actual→
Approved innovative drugs with new targets or mechanisms202511NHSAT12025actual→
Approved innovative drugs with new targets or mechanisms (half year)as of 30 Jun 202611NHSAT12026actual→
Approved novel drugs in breakthrough therapy programs202413NMPAT12024actual→
Beneficiaries of negotiated reimbursement drugs +1 more as of 31 Oct 2024830 millionNHSAT12024actual→
- as of 31 Oct 2024830 millionState CouncilT12024actual→
Bioequivalence trials20252,218NHSAT12025actual→
Bioequivalence trials share202542.5%NHSAT12025actual→
Biologic therapy approvals202540DIAT22025actual→
Bispecific antibody approvals20254DIAT22025actual→
Breast cancer drug approvals20259DIAT22025actual→
Cell therapy approvals20253DIAT22025actual→
Centralized procurement drugs added to national reimbursement drug listas of 28 Nov 20242NHSAT12024actual→
Class 1 innovative drug clinical trials20252,171NHSAT12025actual→
Class 1 innovative drug clinical trials growth rate20254.1%NHSAT12025actual→
Class 1 innovative drug clinical trials share202572.4%NHSAT12025actual→
Clinical trial country use share +2 more 202315%IQVIA2023actual→
Clinical trial registrations +3 more 20255,215NHSAT12025actual→
- 20234,300State CouncilT12023actual→
- 20223,410State CouncilT12022actual→
- 20213,358State CouncilT12021actual→
Clinical trial registrations growth rate20256.4%NHSAT12025actual→
Conventional medicine approvals202580DIAT22025actual→
Cumulative drug approval applications under priority reviewend of 2024496State CouncilT12024actual→
Cumulative drug approval applications under priority review (annual)2020–2024496NMPAT12024actual→
Cumulative drugs added via negotiation in reimbursement drug listas of 28 Nov 2024530NHSAT12024actual→
Cumulative drugs removed from reimbursement drug listas of 28 Nov 2024438NHSAT12024actual→
Cumulative health insurance fund payout for negotiated medicinesas of 31 Oct 2024350 billion CNYState CouncilT12024actual→
Cumulative negotiated drug sales during agreement periodas of 31 Oct 2024510 billion CNYState CouncilT12024actual→
Cumulative newly added drugs in reimbursement drug listas of 28 Nov 2024835NHSAT12024actual→
Cumulative patient burden reduction from negotiated drugsas of 31 Oct 2024880 billion CNYNHSAT12024actual→
Domestic contribution to new entrant increase202581%DIAT22025actual→
Domestic developer drug approvals202563DIAT22025actual→
Domestic developer share of drug approvals202552%DIAT22025actual→
Domestic first-in-class drug approvals +1 more 20254NHSAT12025actual→
Domestic innovative biological product approvals +1 more 202521NHSAT12025actual→
Domestic innovative chemical drug approvals +1 more 202538NHSAT12025actual→
Domestic innovative drug approvals (half year) +1 more as of 30 Jun 202631State CouncilT12026actual→
Domestic share of approved innovative biological products +1 more 202591.3%NHSAT12025actual→
Domestic share of approved innovative chemical drugs +1 more 202580.8%NHSAT12025actual→
Drug approval applications completed under priority review +1 more 2024110State CouncilT12024actual→
Drug clinical trials20255,000NHSAT12025actual→
Drugs in commercial health insurance innovative drug catalog +1 more as of 7 Dec 202519SCIOT12025actual→
- as of 7 Dec 202519State CouncilT12025actual→
Drugs removed from national reimbursement drug list +1 more 202529NHSAT12025actual→
- 202443State CouncilT12024actual→
Drugs removed from national reimbursement drug list (year to date)as of 28 Nov 202443NHSAT12024actual→
First global drug approvals202561DIAT22025actual→
First-in-class drug approvals +8 more 202511NHSAT12025actual→
Fusion protein approvals20253DIAT22025actual→
Health sector research and development investment growth rate20240.1%European CommissionT12025actual→
Imported drug approvals202557DIAT22025actual→
Imported drug share of approvals202548%DIAT22025actual→
Imported innovative biological product approvals +1 more 20252NHSAT12025actual→
Imported innovative chemical drug approvals +1 more 20259NHSAT12025actual→
Innovative biological product approvals +1 more 202523NHSAT12025actual→
Innovative biological product approvals (half year)as of 30 Jun 202617NHSAT12026actual→
Innovative chemical drug approvals +1 more 202547NHSAT12025actual→
Innovative chemical drug approvals (half year)as of 30 Jun 202620NHSAT12026actual→
Innovative drug approvals +4 more 202576NHSAT12025actual→
Innovative drug approvals (half year) +1 more as of 30 Jun 202638State CouncilT12026actual→
Innovative drug approvals (year to date)as of 15 Apr 202614NHSAT12026actual→
Innovative drug licensing-out upfront payment value20257 billion USDMOFCOMT12025actual→
Innovative drug negotiation success rate202490%State CouncilT12024actual→
Innovative drug out-licensing deal count +3 more 2025150NHSAT12025actual→
Innovative drug out-licensing deal count (half year)as of 30 Jun 202681NHSAT12026actual→
Innovative drug out-licensing deal value +4 more 2025130 billion USDNHSAT12025actual→
Innovative drug out-licensing deal value (half year) +3 more as of 30 Jun 2026100 billion USDState CouncilT12026actual→
Innovative drugs added to national health insurance catalog +1 more as of 7 Dec 202550SCIOT12025actual→
- as of 7 Dec 202550State CouncilT12025actual→
Innovative drugs added to national health insurance drug listas of 4 Sep 2026199State CouncilT12026actual→
Innovative drugs approved via priority review pathway +1 more 202417State CouncilT12024actual→
Innovative drugs granted conditional market approval +1 more 202411State CouncilT12024actual→
Innovative traditional medicine approvals +1 more 20256NHSAT12025actual→
Innovative traditional medicine approvals (half year)as of 30 Jun 20261NHSAT12026actual→
International multi-center clinical trials2025410NHSAT12025actual→
International multi-center clinical trials share202513.7%NHSAT12025actual→
Medicine usage index +1 more end of 2030196IQVIA2030forecast→
Medicines added to national health insurance drug listas of 4 Sep 2026949State CouncilT12026actual→
Monoclonal antibody approvals202518DIAT22025actual→
Monoclonal antibody share of new drug approvals202515%DIAT22025actual→
Negotiated or bid drugs added to national reimbursement drug listas of 28 Nov 202489NHSAT12024actual→
Negotiated or bid drugs added to national reimbursement drug list (annual)202489State CouncilT12024actual→
Negotiated pharmaceutical sales driven by medical insuranceas of 28 Feb 2026740 billion CNYNHSAT12026actual→
New drug approvals +1 more 2025120DIAT22025actual→
New drug clinical trial initiation time reduction20254 monthsNHSAT12025actual→
New drug clinical trials +1 more 20252,997NHSAT12025actual→
New drug clinical trials growth rate202518%NHSAT12025actual→
New drug clinical trials share +1 more 202557.5%NHSAT12025actual→
Newly added drugs in national reimbursement drug list +2 more as of 7 Dec 2025114SCIOT12025actual→
- as of 7 Dec 2025114State CouncilT12025actual→
- as of 28 Nov 202491NHSAT12024actual→
Newly added drugs in national reimbursement drug list (annual) +1 more 2025114NHSAT12025actual→
- 202491State CouncilT12024actual→
Novel drug approvals via priority review pathway202417NMPAT12024actual→
Novel drugs granted conditional market approval202411NMPAT12024actual→
Off-catalog drugs participating in price negotiation or biddingas of 28 Nov 2024117NHSAT12024actual→
Pediatric medicine approvals +2 more 2024106NMPAT12024actual→
- 2024106State CouncilT12024actual→
- 2024106NMPAT12024actual→
Peptide therapy approvals20254DIAT22025actual→
Pharmaceutical export delivery value growth (half year) +1 more as of 30 Jun 20269%State CouncilT12026actual→
Pharmaceutical industry export delivery value (half year) +2 more as of 30 Jun 2026210 billion CNYState CouncilT12026actual→
- as of 30 Jun 202630.9 billion USDState CouncilT12026actual→
- as of 30 Jun 2026210 billion CNYMOFCOMT12026actual→
Pharmaceutical industry R&D expenditure growth rate2021–202523%NHSAT12025actual→
Pharmaceutical industry total profit growth rate2021–202511.3%NHSAT12025actual→
Pharmaceutical value-added industrial output growth (half year) +1 more as of 30 Jun 20266.4%State CouncilT12026actual→
Priority review drug approval applications completed growth rate +1 more 202429%State CouncilT12024actual→
Projected patient out-of-pocket burden reduction202550 billion CNYState CouncilT12025forecast→
Radiopharmaceutical market size203026 billion CNYNHSAT12030forecast→
Rare disease drug varieties approved202439State CouncilT12024actual→
Rare disease medicine approvals +2 more 202455NMPAT12024actual→
- 202455State CouncilT12024actual→
- 202455NMPAT12024actual→
Reimbursement drug list conventional medicinesas of 28 Nov 20241,765NHSAT12024actual→
Reimbursement drug list conventional medicines (annual)20251,857NHSAT12025actual→
Reimbursement drug list total drugs +3 more as of 7 Dec 20253,253SCIOT12025actual→
- as of 7 Dec 20253,253State CouncilT12025actual→
- as of 28 Nov 20243,159NHSAT12024actual→
- as of 28 Nov 20243,159State CouncilT12024actual→
Reimbursement drug list total drugs (annual)20253,253NHSAT12025actual→
Reimbursement drug list traditional patent medicinesas of 28 Nov 20241,394NHSAT12024actual→
Reimbursement drug list traditional patent medicines (annual)20251,396NHSAT12025actual→
Sales growth at constant exchange ratesQ1 2026-9%RocheT22026actual→
Sales growth in Swiss francsQ1 2026-12%RocheT22026actual→
Share of global biopharmaceutical licensing deals202520%State CouncilT12025actual→
Share of global biopharmaceutical pipeline +1 more 202530%State CouncilT12025actual→
- 20152%State CouncilT12015actual→
Share of global biopharmaceutical pipeline (snapshot)as of 30 Jun 202630%NHSAT12026actual→
Share of high-value-added products in pharmaceutical exports (half year)as of 30 Jun 202620%MOFCOMT12026actual→
Share of priority review drug approval applications treating cancerend of 202442.5%State CouncilT12024actual→
Share of priority review drug approval applications treating cancer (annual)2020–202442.5%NMPAT12024actual→
Small molecule drug approvals202572DIAT22025actual→
Small molecule share of new drug approvals202560%DIAT22025actual→
Successful price negotiations or bids for off-catalog drugsas of 28 Nov 202489NHSAT12024actual→
Top 50 global pharmaceutical companies countas of 15 Apr 20266NHSAT12026actual→
Type 2 diabetes drug launches20256DIAT22025actual→
Primary documents
Sources
| Document | Publisher | Authority tier | Published | Accessed | Locator | Data points |
|---|---|---|---|---|---|---|
| The 2025 EU Industrial R&D Investment Scoreboard Press release | European Commission | T1 Official | 22 Dec 2025 | 17 Sep 2026 | EU: Health and energy sectors shine in a year of slowdown | 1 |
| 2025年我国批准创新药76个 对外授权超千亿美元 Press release | MOFCOM | T1 Official | — | 17 Sep 2026 | 2025年我国批准创新药76个 对外授权超千亿美元 | 20 |
| 上半年我国创新药对外技术授权交易额创新高 Press release | MOFCOM | T1 Official | — | 17 Sep 2026 | 上半年我国创新药对外技术授权交易额创新高 | 7 |
| 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录 Press release | NHSA | T1 Official | 28 Nov 2024 | 17 Sep 2026 | 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录 | 14 |
| 国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 大众新闻大众日报记者提问; 红星新闻记者提问; 经济日报记者提问 | 7 |
| 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产; 我国上半年创新药对外授权约1100亿美元 创历史新高; 11款新靶点新机制创新药涵盖哪些治疗领域 | 14 |
| 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 试验包括新药临床试验和生物等效性试验; 新药临床试验近六成 其中超七成是创新药; 从“0”到“1”创新能力增强 我国新药研发热度持续攀升 | 14 |
| 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录 | 7 |
| 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 创新高！去年我国批准创新药76个 对外授权破千亿美元 | 17 |
| Measures facilitate approval of 48 first-in-class innovative drugs Press release | NMPA | T1 Official | — | 17 Sep 2026 | Measures facilitate approval of 48 first-in-class innovative drugs | 13 |
| China approves 48 innovative drugs in 2024 Press release | NMPA | T1 Official | — | 17 Sep 2026 | China approves 48 innovative drugs in 2024 | 6 |
| China updates national medical insurance catalog, adds 114 new drugs Press release | SCIO | T1 Official | — | 17 Sep 2026 | China updates national medical insurance catalog, adds 114 new drugs | 4 |
| Measures facilitate approval of 48 first-in-class innovative drugs Press release | State Council | T1 Official | — | 17 Sep 2026 | Measures facilitate approval of 48 first-in-class innovative drugs | 12 |
| 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网 Press release | State Council | T1 Official | — | 17 Sep 2026 | 7年累计将835种药品新增进入目录; 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药; “全球新”的创新药有38种，创历年新高 | 10 |
| China scales up support for clinical trials, accelerating drug development Press release | State Council | T1 Official | — | 17 Sep 2026 | China scales up support for clinical trials, accelerating drug development | 3 |
| Value of China's innovative drug out-licensing deals hit new high in H1 Press release | State Council | T1 Official | — | 17 Sep 2026 | Value of China's innovative drug out-licensing deals hit new high in H1 | 7 |
| China updates national medical insurance catalog, adds 114 new drugs Press release | State Council | T1 Official | — | 17 Sep 2026 | China updates national medical insurance catalog, adds 114 new drugs | 4 |
| 全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网 Press release | State Council | T1 Official | — | 17 Sep 2026 | 大力支持产业创新; 更好满足临床急需 | 2 |
| China to expand health insurance coverage for innovative drugs Press release | State Council | T1 Official | — | 17 Sep 2026 | China to expand health insurance coverage for innovative drugs | 6 |
| 2025 NMPA Approvals: China Clears Record Number of New Drugs Press release | DIA | T2 National | — | 17 Sep 2026 | Established Modalities Maintain a Larger Presence; 2025 NMPA Approvals: China Clears Record Number of New Drugs; The Cancer Sector Continues to Attract the Most Players | 20 |
| [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a... Press release | Roche | T2 National | 23 Jul 2026 | 15 Sep 2026 | Group results | 2 |
| Rethinking Clinical Trial Country Prioritization Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Key findings:; Country utilization is heavily consolidated in U.S., China and Western European countries | 3 |
| Global Medicine Use Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Report Summary: | 2 |
Report snapshots are retained internally for verification only and are never redistributed. Where a figure comes from a paywalled report, only the number published in its public summary is recorded.
All 195 collected records for China are published as verified.
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. Each figure's own page carries APA, MLA, Chicago and BibTeX citations naming its original publisher.
StatOrigin. (2026). Pharmaceuticals in China: statistics. Retrieved from https://statorigin.org/industries/pharmaceuticals/china